Fig. 4: ADT-upregulated TCF7L1 promotes the NED of PCa.
From: TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer
A TCF7L1, CHGA, ENO2, NKX3-1, and KLK3 protein levels in various PCa cell lines as determined by immunoblotting. B RT-qPCR showing mRNA levels of TCF7L1, NE markers (CHGA, CHGB, SYP, and ENO2), and androgen-responsive genes (NKX3-1 and KLK3) in LNCaP and C4-2 cells following stable transfection with an empty vector (EV) or a TCF7L1 cDNA vector. *p < 0.05, **p < 0.01, ***p < 0.001. C TCF7L1, CHGA, ENO2, NKX3-1, and KLK3 protein levels in C4-2 and LNCaP cells following stable transfection with an EV or TCF7L1 expression vector, by immunoblotting. D mRNA levels of TCF7L1 and NE markers in PC3 and LASCPC01 cells following stable transfection with nontarget control (NC) or TCF7L1 shRNA vectors, by an RT-qPCR analysis. * vs. the NC. E TCF7L1, CHGA, ENO2, and SYP protein levels in PC3 and LASCPC01 cells expressing the NC or TCF7L1 shRNA. F mRNA levels of TCF7L1, NE markers, and androgen-responsive genes in LNCaP and C4-2 cells expressing the NC or TCF7L1 shRNA following treatment of cells with FBS-containing or CSS-containing medium for 10 days, by an RT-qPCR analysis. * vs. FBS; # vs. the NC. Data from the quantification of mRNA are presented as the mean ± SEM, n = 3 per group; by a two-way ANOVA. G Immunoblots showing TCF7L1, CHGA, ENO2, NKX3-1, and KLK3 protein levels in C4-2 and C4-2-MDVR cells expressing the NC or TCF7L1 shRNA.
